Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: a pilot study

J Int Med Res. Nov-Dec 2009;37(6):1961-71. doi: 10.1177/147323000903700634.


This pilot study evaluated the survival of patients with end-stage cancer who received supplements of coenzyme Q(10) and a mixture of other antioxidants (e.g. vitamin C, selenium, folic acid and beta-carotene). During a period of 9 years, 41 patients who had end-stage cancer were included. Forty patients were followed until death and one patient was lost to follow-up and presumed dead. Primary cancers were located in the breast, brain, lungs, kidneys, pancreas, oesophagus, stomach, colon, prostate, ovaries and skin. The median predicted survival time was calculated from Kaplan-Meier curves for each patient at inclusion. Median predicted survival was 12 months (range 3 - 29 months), whereas median actual survival was 17 months (1 - 120 months), which is > 40% longer than the median predicted survival. Mean actual survival was 28.8 months versus 11.9 months for mean predicted survival. Ten patients (24%) survived for less time than predicted, whereas 31 (76%) survived for longer. Treatments were very well tolerated with few adverse effects.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antioxidants / adverse effects
  • Antioxidants / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / drug therapy*
  • Pilot Projects
  • Survival Analysis
  • Terminally Ill*
  • Time Factors
  • Ubiquinone / adverse effects
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / therapeutic use


  • Antioxidants
  • Ubiquinone
  • coenzyme Q10